



EHDN Clinical Research Congress 2026 22nd – 24th October 2026, Kraków, Poland

**Preliminary programme – status Sept 10*

THURSDAY, 22nd OCTOBER, 2026

07:30 – 08:30 REGISTRATION DESK

08:30 – 09:00 WELCOME AND INTRODUCTION

Chaired by Patrick Weydt, Cristina Sampaio and Danuta Lis

09:00 – 09:45 PLENARY SESSION I: HD Burden - Family and Patient Perspective

Chaired by Åsa Petersén

Speakers: Charlotte Spearing, Greg Witkowski, William Gray and Marianna Ellison-Klimontowicz

09:45 – 10:30 PLENARY SESSION II: Navigating the Therapeutic Pipeline in Huntington's Disease

Chaired by Swati Sathe and Pavlina Stefanova-Konstantinova

1. **The Race to treat Huntington's disease: where have we come over the past decade**
Anne Rosser
2. **Future Challenges and Opportunities in the Clinical Development of Huntington's Disease Therapies**
Cristina Sampaio
3. **Panel Discussion and Q&A**

10:30 – 11:00 **BREAK**

11:00 – 12:00 PARALLEL SESSIONS I

A. Learning Across Neurodegenerative Diseases: Clinical Trial Innovation, Design, and Ethics

Chaired by Patrick Weydt and Ruben van Eijk

1. **Lessons and innovations in clinical trials for Amyotrophic Lateral Sclerosis**
Ruben van Eijk
2. **Looking back - looking forward: insights into clinical trial design and determination of clinical meaningfulness**
Michael Hayden
3. **Placebo-controlled surgical trials: an ethical overview**
Cindy Towns

B. Psychological interventions in Huntington's Disease: a transdiagnostic perspective

Chaired by Docia Demmin and Lucienne Van der Meer

1. **Keeping Yourself in Mind: Acceptance and Commitment Therapy programmes for people affected by Huntington's Disease**
Sarah Gunn
2. **Resilient together-ALS: an early dyadic intervention for patients and their informal care-partners**
Christina Rush
3. **Reducing anxiety in people with HD using a guided self-help intervention**
Jane Simpson and Maria Dale

12:00 – 13:30 **LUNCH and POSTER VIEWING**



13:30 – 14:30

PARALLEL SESSIONS II

A. Digital Biomarkers and Artificial Intelligence

Chaired by Jean-Marc Burgunder and Matt Roche

1. Sensitivity, Validity, and Utilization of the HD Digital Motor Score in Clinical Trials

Jonas Dorn

2. Q-Motor Outcomes at 3 Years after AMT-130 HTT-Lowering Gene Therapy

David Margolin

3. AI-Powered Digital Twins: Applications and Opportunities in Clinical Trials

Ann-Kathrin Schalkamp

4. Panel Discussion and Q&A

B. Social Cognition

Chaired by Sarah Mason and Rebecca Fuller

1. Reading minds missing people: Ecological validity problem in social cognition

Erin Heerey

2. Cling Film, Text Messages and Work - Three ethnographic stories of early social cognitive change in Huntington's disease

Alex Fisher and Clare Eddy

3. Talk III

TBA

4. Panel Discussion and Q&A

14:30 – 14:35

Transition BREAK

14:35 – 15:15

EHDN BUSINESS MEETING

Chaired by Patrick Weydt and Åsa Petersén

15:15 – 15:45

BREAK

15:45 – 16:45

KEYNOTE LECTURE I: Genetic Testing and Genetic Modifiers

Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

Speaker: Alexandra Durr

16:45 – 17:45

DEBATE: Implementation of Genetic Modifier Data into Clinical Practice – Are we there, yet?

Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

Speaker: Michael Hayden, Alexandra Durr, Robert Klitzman, Ashleigh Mclellan and Darren Monckton

17:45 – 22:00

NETWORKING EVENING

Posters, Art Exhibition, Finger Food & Drinks



FRIDAY, 23rd OCTOBER, 2026

08:00 – 08:45 PLENARY SESSION III: Access and Affordability for the HD Community

Chaired by Hugh Rickards and Jenna Heilman

1. **HEATED (Huntington's Equal Access to Effective Drugs). The story so far.**
Hugh Rickards
2. **Access to effective HD drugs: the global perspective**
Ignacio Muñoz-Sanjuan
3. **What are the barriers to access to effective drugs in HD and how do we overcome them?**
Josie Godrey
4. **Panel Discussion and Q&A**

08:45 – 09:45 UPDATE ON ONGOING CLINICAL TRIALS

Chaired by Jenny Townhill and Ralf Reilmann

1. **Alnylam**
Sarah Tabrizi
2. **VICO Therapeutics**
Scott Schobel
3. **Skyhawk Therapeutics**
Meghan Miller
4. **Placebo Response in Recent HD Randomized Clinical Trials**
Jeffrey Long
5. **Panel Discussion and Q&A**

09:45 – 10:00 BREAK

10:00 – 11:00 PARALLEL SESSIONS III

A. Modifiers of Huntington's Disease: Genetic, Biological, and Preclinical Perspectives

Chaired by Marta Biagioli and Vahri Beaumont

1. **PMS1/MLH1 variants and drugging the PMS1 ATPase site**
Tom Massey
2. **MED15 as a Non-MMR Modifier of Huntington's Disease**
Mahmoud Pouladi
3. **hiPSC cell models**
Mike Flowers

B. Glymphatic Imaging

Chaired by Daniel Claassen and Andrew Wood

1. **Why the Glymphatic System Deserves Our Attention**
Daniel Classen
2. **Imaging Human Glymphatic Function with Intrathecal Contrast: From Method to Clinical Readout**
Per Kristian Eide
3. **Imaging the Glymphatic System in Huntington's Disease and Neurodegeneration: Implications for Monitoring and Neurotherapeutics**
Manus Donahue

11:00 – 11:30 BREAK

11:30 – 12:30 KEYNOTE LECTURE II: The ubiquitin proteolytic system - from a hypothetical assumption of why it should exist to human diseases and drug development

Chaired by Hoa Huu Phuc Nguyen

Speaker: Prof. Dr. Aaron Ciechanover (Nobel Prize Winner for Chemistry 2004)



- 12:30 – 14:30 **LUNCH, POSTER VIEWING and SPECIAL SESSIONS**
- | | | |
|---|--|--|
| <p>a. HDYO and EHA
13:15–14:15
Chaired by Jenna Heilman and Astri Arnesen</p> | <p>b. EHDN/MDS-ES Fellowships Meeting
13:15–14:15
Chaired by Juliana Bronzova and Fionnuala Margreiter</p> | <p>c. Local Language Session
13:00–15:30
Chaired by Danuta Lis and Daniel Zielonka</p> |
|---|--|--|
- 14:30 – 15:30 **SHORT COMMUNICATIONS I**
Presentation of selected abstracts
Chaired by Davina Hensman Moss and Jiří Klempíř
- 15:30 – 16:30 **PLENARY SESSION IV: Advanced Biomarkers**
Chaired by Hilary Wilkinson and Niels Skotte
1. **Lipidomics and new biomarkers**
William Griffiths
 2. **PENK & NEFL**
Niels Skotte and Hilary Wilkinson
 3. **HD YAS 3.0**
Rachael Scahill
- 16:30 – 17:00 **BREAK**
- 17:00 – 18:00 **PANEL DISCUSSION: Clinical Trial Communications in Context - Rules, Responsibilities, and Community Expectations**
Chaired by Emily Gantman and Ed Wild
Panel: Charlotte Spearing, Mai-Lise Nguyen, Rachel Harding and David Anderson

SATURDAY, 24th OCTOBER, 2026

- 08:30 – 09:15 **EHDN LIGHTNING PRESENTATIONS**
Chaired by Duncan McLauchlan and Agnieszka Fiszer
1. **Lightning Presentation on awarded EHDN Strategic Funds**
Nayana Lahiri, Camilla Ekwall and Cheney Drew
 2. **The expanded HTT CAG repeat is a DNA repair hotspot where unscheduled DNA synthesis serves as a sensitive biomarker of somatic instability**
Verónica Inés Brito
 3. **LTS-201: An AAV Gene Therapy Targeting MSH3 for Huntington's Disease**
Jang-Ho Cha
 4. **LQT-23: a small molecule MSH3 inhibitor targeting somatic instability in Huntington's disease**
Caroline L. Benn
- 09:15 – 10:15 **PLENARY SESSION V: Efficacy Demonstration - Standards, Measures and Endpoints**
Chaired by Ahmad Aziz and Jamie Hamilton
1. **Analysis of Enroll-HD TMS training data**
Matt Roche
 2. **Analytical Considerations for Contextualizing Outcomes and Estimating Treatment Effects in Huntington's Disease Clinical Trials with Partial or no Internal Control Using External Cohort Data**
Angelika Caputo
 3. **MCID within the context of other Neurodegenerative disorders**
Glenn Stebbins



10:15 – 10:45 **BREAK**

10:45 – 11:45 **SHORT COMMUNICATIONS II**
Presentation of selected abstracts
Chaired by Mayke Oosterloo and Arun Karpur

11:45 – 12:45 **From Clinical Trial Progress and Regulatory Perspectives**
Chaired by Bernhard Landwehrmeyer and Daniel Weintraub

- 1. Regulatory perspectives on trial innovation and clinical meaningful outcomes**
Elena Hernández Martínez de Lapiscina
- 2. Tominersen: GENERATION HD2 Results and Key Learnings**
Peter McColgan
- 3. Votoplam: Phase 2 Results and Phase 3 INVEST-HD study update**
Beth Borowsky
- 4. Panel Discussion and Q&A**
Elena Hernández Martínez de Lapiscina, Peter McColgan, Beth Borowsky, Anne Rosser and Dina De Sousa

12:45 – 13:10 **SUMMARY AND POSTER AWARD**
Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

13:10 – 13:15 **FAREWELL**
Chaired by Patrick Weydt and Cristina Sampaio